4.3 Article

Fusion of Na-ASP-2 with human immunoglobulin Fcγ abrogates histamine release from basophils sensitized with anti-Na-ASP-2 IgE

期刊

PARASITE IMMUNOLOGY
卷 34, 期 8-9, 页码 404-411

出版社

WILEY
DOI: 10.1111/j.1365-3024.2012.01371.x

关键词

allergy; Fc?RIIb; FceRI; hookworm; IgE; Na-ASP-2; Necator americanus; vaccine

资金

  1. Sabin Vaccine Institute's Human Hookworm Vaccine Initiative
  2. Bill & Melinda Gates Foundation

向作者/读者索取更多资源

Na-ASP-2 is a major protein secreted by infective third-stage larvae (L3) of the human hookworm Necator americanus upon host entry. It was chosen as a lead vaccine candidate for its ability to elicit protective immune responses. However, clinical development of this antigen as a recombinant vaccine was halted because it caused allergic reactions among some of human volunteers previously infected with N.similar to americanus. To prevent IgE-mediated allergic reactions induced by Na-ASP-2 but keep its immunogenicity as a vaccine antigen, we designed and tested a genetically engineered fusion protein, Fc?/Na-ASP-2, composed of full-length Na-ASP-2 and truncated human IgG Fc?1 that targets the negative signalling receptor Fc?RIIb expressed on pro-allergic cells. The chimeric recombinant Fc?/Na-ASP-2 protein was expressed in Pichia pastoris and shared the similar antigenicity as native Na-ASP-2. Compared to Na-ASP-2, the chimeric fusion protein efficiently reduced the release of histamine in human basophils sensitized with anti-Na-ASP-2 IgE obtained from individuals living in a hookworm-endemic area. In dogs infected with canine hookworm, Fc?/Na-ASP-2 resulted in significantly reduced immediate-type skin reactivity when injected intradermally compared with Na-ASP-2. Hamsters vaccinated with Fc?/Na-ASP-2 formulated with Alhydrogel (R) produced specific IgG that recognized Na-ASP-2 and elicited similar protection level against N.similar to americanus L3 challenge as native Na-ASP-2.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据